Systematic Follow up of Second Line Treatments for Parkinson's Disease (Deep Brain Stimulation, Apomorphin Pump, Duodopa Pump)

Status: Not yet recruiting
Location: See location...
Study Type: Observational
SUMMARY

Primary purpose: Fluctuations and dyskinesia evolution in Parkinson's disease patients, one year after initiation of deep brain stimulation, apomorphin pump or duodopa pump Secundary purposes: Motor complications evolution at 6 months, 2 and 3 years MDS UPDRS III score at 6 months, 1, 2 and 3 years non motor complications evolution at 6 months, 1, 2 and 3 years cognition and psychiatric complications evolution at 6 months, 1, 2 and 3 years cutaneous and digestive complications at 6 months, 1, 2 and 3 years neuropathy occurrence at 6 months, 1, 2 and 3 years medical treatment and Levodopa equivalent dose modifications at 6 months, 1, 2 and 3 years

Eligibility
Participation Requirements
Sex: All
Minimum Age: 21
Healthy Volunteers: No
View:

• Parkinson disease (UKPDSSB criteria)

• Patient with fluctuations and/or dyskinesia , who need treatment with deep brain stimulation, apomorphin pump or duodopa pump

• MOCA >20

• patient >21 years of age

• patient who has signed protocol acceptation

Locations
Other Locations
France
Mathieu ANHEIM
Strasbourg
Contact Information
Primary
Mathieu ANHEIM
mathieu.anheim@chru-strasbourg.fr
+33 3 88 12 85 35
Time Frame
Start Date: February 2022
Estimated Completion Date: March 2028
Participants
Target number of participants: 150
Authors
Sponsors
Leads: University Hospital, Strasbourg, France

This content was sourced from clinicaltrials.gov

Similar Clinical Trials